Literature DB >> 22652643

GST P1, a novel downstream regulator of LRRK2, G2019S-induced neuronal cell death.

Jie Chen1, Anthony Liou, Lili Zhang, Zhongfang Weng, Yanqin Gao, Guodong Cao, Michael J Zigmond, Jun Chen.   

Abstract

The enhanced neurotoxicity of the Parkinson's disease-associated LRRK2 mutant, G2019S, than its wild-type counter-part has recently been reported. Overexpression of LRRK2 (G2019S) in cultured neural cells results in caspase-3-dependent apoptosis via a yet undefined signaling pathway. Elucidation of the mechanism underlying LRRK2 (G2019S) neurotoxicity may offer new insights into the pathogenesis of Parkinson's disease. In this study, we identified glutathione s-transferase P1 (GSTP1) as a selective target whose expression is negatively regulated at the transcriptional levels via promoter hyper-methylation by LRRK2 (G2019S). Overexpression of LRRK2 (G2019S) in the human neuronal cell line SH-SY5Y markedly suppressed the expression of GSTP1 prior to any manifestation of cell death. Moreover, shRNA-mediated knockdown of endogenous GSTP1 expression exacerbated LRRK2 (G2019S) neurotoxicity, whereas overexpression of GSTP1 protected against LRRK2 (G2019S)-induced caspase-3 activation and neuronal apoptosis. In conclusion, the results suggest a previously undefined signaling mechanism underlying the neurotoxic effect of LRRK2 (G2019S), in which LRRK2 (G2019S) triggers oxidative stress in cells and, in turn, results in caspase-dependent apoptosis at least in part by suppressing the expression of GSTP1.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22652643      PMCID: PMC4174408          DOI: 10.2741/e548

Source DB:  PubMed          Journal:  Front Biosci (Elite Ed)        ISSN: 1945-0494


  38 in total

Review 1.  Roc, a Ras/GTPase domain in complex proteins.

Authors:  Leonard Bosgraaf; Peter J M Van Haastert
Journal:  Biochim Biophys Acta       Date:  2003-12-07

2.  Biochemical and pathological characterization of Lrrk2.

Authors:  Benoit I Giasson; Jason P Covy; Nancy M Bonini; Howard I Hurtig; Matthew J Farrer; John Q Trojanowski; Vivianna M Van Deerlin
Journal:  Ann Neurol       Date:  2006-02       Impact factor: 10.422

3.  Hsp27 protects against ischemic brain injury via attenuation of a novel stress-response cascade upstream of mitochondrial cell death signaling.

Authors:  R Anne Stetler; Guodong Cao; Yanqin Gao; Feng Zhang; Suping Wang; Zhongfang Weng; Peter Vosler; Lili Zhang; Armando Signore; Steven H Graham; Jun Chen
Journal:  J Neurosci       Date:  2008-12-03       Impact factor: 6.167

4.  Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics.

Authors:  Denise M Kay; Cyrus P Zabetian; Stewart A Factor; John G Nutt; Ali Samii; Alida Griffith; Tom D Bird; Patricia Kramer; Donald S Higgins; Haydeh Payami
Journal:  Mov Disord       Date:  2006-04       Impact factor: 10.338

Review 5.  Glutathione transferases.

Authors:  John D Hayes; Jack U Flanagan; Ian R Jowsey
Journal:  Annu Rev Pharmacol Toxicol       Date:  2005       Impact factor: 13.820

6.  HBx genotype D represses GSTP1 expression and increases the oxidative level and apoptosis in HepG2 cells.

Authors:  Dandan Niu; Jianhua Zhang; Yudan Ren; Huixing Feng; Wei Ning Chen
Journal:  Mol Oncol       Date:  2008-11-01       Impact factor: 6.603

7.  Reduction of GSTP1 expression by DNA methylation correlates with clinicopathological features in pituitary adenomas.

Authors:  YunFeng Yuan; Zhi Rong Qian; Toshiaki Sano; Sylvia L Asa; Shozo Yamada; Noriko Kagawa; Eiji Kudo
Journal:  Mod Pathol       Date:  2008-04-18       Impact factor: 7.842

Review 8.  LRRK2 in Parkinson's disease: biochemical functions.

Authors:  Vasanti S Anand; Steven P Braithwaite
Journal:  FEBS J       Date:  2009-10-05       Impact factor: 5.542

9.  The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro.

Authors:  Christian Johannes Gloeckner; Annette Schumacher; Karsten Boldt; Marius Ueffing
Journal:  J Neurochem       Date:  2009-03-03       Impact factor: 5.372

10.  The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor.

Authors:  S Goldwurm; A Di Fonzo; E J Simons; C F Rohé; M Zini; M Canesi; S Tesei; A Zecchinelli; A Antonini; C Mariani; N Meucci; G Sacilotto; F Sironi; G Salani; J Ferreira; H F Chien; E Fabrizio; N Vanacore; A Dalla Libera; F Stocchi; C Diroma; P Lamberti; C Sampaio; G Meco; E Barbosa; A M Bertoli-Avella; G J Breedveld; B A Oostra; G Pezzoli; V Bonifati
Journal:  J Med Genet       Date:  2005-11       Impact factor: 6.318

View more
  3 in total

Review 1.  Glutathione metabolism and Parkinson's disease.

Authors:  Michelle Smeyne; Richard Jay Smeyne
Journal:  Free Radic Biol Med       Date:  2013-05-08       Impact factor: 7.376

Review 2.  Environmental Impact on the Epigenetic Mechanisms Underlying Parkinson's Disease Pathogenesis: A Narrative Review.

Authors:  Efthalia Angelopoulou; Yam Nath Paudel; Sokratis G Papageorgiou; Christina Piperi
Journal:  Brain Sci       Date:  2022-01-28

3.  Parkinson's disease: a complex interplay of mitochondrial DNA alterations and oxidative stress.

Authors:  Sarah Ciccone; Emiliano Maiani; Giovanna Bellusci; Marc Diederich; Stefania Gonfloni
Journal:  Int J Mol Sci       Date:  2013-01-24       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.